

## CURRICULUM VITAE

September 2007

### Jack E. Ansell, M.D.

**Home Address:** 31 Devonshire Road  
Newton, MA 02468  
(617) 964-6229

**Business Address:** Department of Medicine - E 113  
Boston University Medical Center  
88 East Newton Street  
Boston, MA 02118  
Phone: (617)638-7250  
Fax: (617) 638- 8728  
email: jack.ansell@bmc.org

**Current Position:** **Vice Chairman for Clinical Affairs,  
Department of Medicine**  
Boston University School of Medicine and  
Boston Medical Center  
**Professor of Medicine**  
Boston University School of Medicine  
  
**Interim Chief, Section of Hematology/Oncology**  
Boston University School of Medicine and  
Boston Medical Center

### EDUCATION:

BA, University of Virginia, Charlottesville, VA, 1964 – 1968  
MD, University of Virginia School of Medicine, Charlottesville, VA, 1968 - 1972

### POSTDOCTORAL TRAINING:

Internship (PG 1)  
Tufts - New England Medical Center, Boston, MA  
Medicine, 1972 - 1973  
  
Residency (PG 2)  
Tufts - New England Medical Center, Boston, MA  
Medicine, 1973 - 1974  
  
Fellowship (PG 3-5)  
Boston University/Boston City Hospital, Boston, MA  
Hematology, 1974 - 1975  
  
Veterans Administration Hospital, Boston, MA  
Hematology/Hemostasis, 1975 - 1977

### BOARD CERTIFICATION:

Virginia State Boards, Part I, 1970  
Virginia State Boards, Part II, 1972  
Diplomat, American Board of Internal Medicine, 1975  
Diplomat, American Board of Internal Medicine (Hematology), 1976

**LICENSURE:**

Virginia, No. 21916 (Inactive), 1972

Massachusetts, No. 36584, 1974

**ACADEMIC APPOINTMENTS:**

Research Associate in Medicine

Boston University School of Medicine, 1974 - 1975

Assistant Professor of Medicine and Pathology

University of Massachusetts Medical School, 1977 - 1981

Associate Professor of Medicine and Pathology

University of Massachusetts Medical School, 1981 - 1988

Professor of Medicine and Pathology

University of Massachusetts Medical School, 1988 - 1994

Professor of Medicine

Boston University School of Medicine, 1994 -

**HOSPITAL APPOINTMENTS:**

Attending Physician, Division of Hematology/Oncology

University of Massachusetts Medical Center, 1977 - 1994

Interim Director, Division of Hematology/Oncology

University of Massachusetts Medical Center, 1990 - 1992

Vice Chairman, Department of Medicine

University of Massachusetts Medical Center, 1992 - 1994

Medical Director, Ambulatory Care

University of Massachusetts Medical Center, 1993 - 1994

Vice Chairman for Clinical Affairs, Department of Medicine

Boston University Medical Center, 1994 -

Medical Director, Boston University Medical Group

Boston University Medical Center, 1994 -

(clinical enterprise of the Department of Medicine with over 200,000 ambulatory visits and 17,000 inpatient admissions)

Chairman, Department of Medicine

Quincy Medical Center, 1999-2000

(a community hospital teaching affiliate of Boston Medical Center acquired in 1999; served as chair until permanent chair recruited)

Interim Chief, Section of Hematology/Oncology

Boston University Medical Center, 2004-

**PROFESSIONAL SOCIETIES:**

American College of Physicians, Fellow

American Society of Hematology

American Heart Association, Fellow, Council on Arteriosclerosis, Thrombosis, and Vascular Biology

International Society of Thrombosis and Hemostasis

ISTH Scientific Subcommittee on Hemostasis Testing

Worcester District Medical Society, President 1988 - 1990

Massachusetts Medical Society

American Medical Association

Cancer and Leukemia Group B, 1980 - 1995

Anticoagulation Forum, Chairman and founder 1991 -

International Self-Management of Oral Anticoagulation Association, President and founder 2001 -

**HONORS:**

AAMC/PHS International Fellowship (Israel), 1972

Outstanding Teaching Award in Basic Sciences (Runner-Up), 1982

Outstanding Teaching Award in Basic Sciences, 1987  
Wisteria Award, Worcester District Medical Society, 1990  
Jason Vitale Memorial Award, Massachusetts Chapter, Leukemia Society of America, 1994

## **SELECTED HOSPITAL & MEDICAL SCHOOL ACTIVITIES**

### **Boston University Medical Center 1994 -**

Medical Director, Boston University Medical Group, 1994 -  
Board of Directors, Evans Medical Foundation, 1994 - 1998  
Dean's Task Force for Creation of Department of Family Practice, 1995  
Anticoagulation Task Force, 1995-  
Search Committee, Department of Psychiatry Chair, 1995  
Information Services Executive Committee, 1995 - 1997  
Information Services Steering Committee, 1995 - 1997  
Director, Anticoagulation Clinic, 1995 -  
Member, Boston Medical Center Utilization Review Committee, 1995 - 1998  
Admissions Process Steering Committee, 1996  
Member, BMC Exclusive Provider Organization Development Task Force, 1996  
Member, Boston Medical Associates IPA Board of Directors, 1996 - 1998  
Member, HealthNet Medical Directors Committee 1996 -  
Chair, Ambulatory Services Committee, 1996 - 1999  
Member, Boston Medical Center Marketing Steering Committee, 1997  
Member, Boston Medical Center HealthNet Plan, Quality & Clinical Management Committee, 1998 -  
Member, Boston Medical Center Quality Council, 1998 - 2000  
Search Committee, Department of Urology Chair, 1999  
Member, Boston Medical Center Medical Management Council, 1999 -  
Medical Student Advisor Program 2000 -  
Chief of Medicine, Quincy Medical Center, 1999 - 2000  
Chair, Search Committee for Chief of Oncology, Boston VAMC, 2001  
Search Committee, Department of Ophthalmology Chair, 2002  
Member, Department of Medicine Conflict of Interest Policy Development Group, 2002  
Search Committee, Section of Hematology/Oncology Chief, 2003  
Member, Board of Directors, Faculty Practice Plan Foundation, 2005 -  
Member, MSO Subcommittee of Faculty Practice Plan, 2005 -  
Member, Boston Medical Center Cancer Committee, 2005 -

### **University of Massachusetts Medical Center 1977 - 1994**

Medical Director, Ambulatory Care, University of Massachusetts Medical Center  
Chairman, Ambulatory Care Committee (policy and oversight of Amb Care Program for UMMC)  
Director, Anticoagulation Service  
Director, Medical Specialties Clinic  
Ambulatory Care Task Group (Developed Hospital-Group Practice Model for Ambulatory Care)  
Director, UMMC Affiliated Hematology/Oncology Fellowship Program  
(Established and directed a joint training program with three other community hospitals)  
Hospital Executive Committee  
UMMC Clinical Growth Task Force  
Group Practice Advisory Board  
Utilization Review Committee  
Cancer Committee  
Transfusion Review Committee  
Department of Medicine Residency Committee  
Housestaff and Medical Student Advisory Program  
Director, Fellowship Program, Division of Hematology/Oncology  
Chairman, Department of Medicine Incentive Program Development Committee  
(developed Incentive Plan for Department of Medicine Faculty)  
Coordinator, Topics in Medicine (continuing medical education outreach program for the Department of Medicine and Medical Center)

## **SELECTED PROFESSIONAL ACTIVITIES**

Fellow, American College of Physicians

Chairman, Health & Public Policy Committee, ACP Massachusetts Chapter, 1992 - 1998

Governor's Council, ACP, Massachusetts Chapter, 1994-2003

Massachusetts Medical Society

Executive Councilor, Massachusetts Medical Society

Member, Nominating Committee

Chairman, Professional Credentials Verification Service Advisory Committee 1996 - 2000

Member, Academic Medical Section, Massachusetts Medical Society, 1997 - 1998

Member, Committee on Publications, 1997 -

Delegate, Suffolk District Medical Society, 2000 - 2005

President, Worcester District Medical Society, 1988 – 1990

Founder and Chairman, Anticoagulation Forum (a Nat'l network of Anticoagulation Clinics), 1991 – 2007

Co-Founder and President, International Self-Management of Oral Anticoagulation Association, 2001-

Member, Board of Trustees, Quincy Medical Center 2004 -

Trustee, Boston Medical Library, 2006 -

### **Editorial Activities:**

Senior Associate Editor, Journal of Thrombosis & Thrombolysis, 1995 -

Editorial Advisory Board, Current Clinical Pharmacology, 2005-

Editorial Advisory Board, Journal of Thrombosis & Hemostasis, 2005 -

Manuscript Reviewer:

New England Journal of Medicine

Annals of Internal Medicine

Archives of Internal Medicine

American Journal of Medicine

Thrombosis & Haemostasis

Journal of Thrombosis & Hemostasis

Thrombosis Research

Blood

Circulation

Chest

Lancet

American Journal of Clinical Pathology

Journal of Cardiovascular Drugs

Mayo Clinic Proceedings

Drug Evaluations, AMA Drug Compendium

Expert Review of Cardiovascular Therapy

### **Scientific Committees, Advisory Boards, etc:**

Chairman, Ad Hoc Clinical Advisory Board, Boehringer Mannheim Corporation, 1996

Consultant, FDA Hematology and Pathology Devices Panel and Center for

Devices and Radiological Health, 1997 –

Member, College of American Pathologist Consensus Conference on Laboratory

Monitoring of Anticoagulants, 1997

Member, NCCLS Subcommittee on "Point-of-Care Hemostasis/Coagulation Testing" 1998 – 2003

Chair, NCCLS Subcommittee on "Point-of-Care Hemostasis/Coagulation Testing" 2004 -

Member, American College of Chest Physicians Consensus Conference on

Antithrombotic Therapy, 1998, 2001, 2004, 2007

Chair, Oral Anticoagulation Therapy Committee, American College of Chest Physicians Consensus Conference on Antithrombotic Therapy, 2001, 2004, 2007

Chair, Perioperative Management of Antithrombotic Therapy Committee, American College of Chest Physicians Consensus Conference on Antithrombotic Therapy, 2007

Member, Scientific Advisory Board, Instrumentation Laboratories, 2001 –  
Member, Scientific Advisory Committee, St. Jude Heart Valve Company, 2002 -  
Member, ad hoc Advisory Panels:  
Wyeth Ayerst, Aventis, Centocor, Yamanouchi, AstraZeneca, Eli Lilly, Boehringer Ingelheim  
Hemosense, International Technidyne, Roche Diagnostics, Novartis, Bayer, Daiichi, Aryx  
Aton Pharma, Bristol Myers Squibb  
Member, National Advisory Board, University of Southern Indiana Anticoagulation Therapy  
Management Certificate Program  
Medical Advisor – Anticoagulation Specialty Council for the College of Pharmacists of British  
Columbia, Canada, 2003 –  
Member, Advisory Board, ClotCare web site 2004 -  
Member, Medical & Scientific Advisory Board, National Alliance for Thrombosis and  
Thrombophilia, 2005-  
Surgeon General's Workshop on Deep Vein Thrombosis, 2006; an NHLBI sponsored  
Workshop  
VTE Treatment Global Advisory Council, Scios / Bayer, 2006  
Chair, Atrial Fibrillation Advisory Board, BMS, 2007

**Clinical Trial Steering Committees, Data Safety Monitoring Boards, etc:**

Chairman, Special Advisory Board, AHCPR Stroke PORT Study, David Matchar (PI),  
Duke University, 1996  
Member, Data Safety Monitoring Board, Wyeth-Ayerst Normoflo Study, 1996 – 1997  
Chairman, Data Safety Monitoring Committee, Study DPC 906-201, A phase II, randomized, double-  
blind active-controlled (enoxaparin), parallel group, dose-response study of DPC 906 for the  
prevention of deep vein thrombosis in knee replacement surgery, 2001-2002  
Member, Steering Committee, Protocol #223 (SH-TPV-005), A double-blind, efficacy and safety study  
of the oral direct thrombin inhibitor, H 376/95 versus standard therapy (enoxaparin and warfarin) in  
patients with acute, symptomatic deep venous thrombosis with or without pulmonary embolism  
(THRIVE V) 2001-2002  
Member, Data Safety Monitoring Committee, Oral Direct Factor Xa Inhibitor BAY 59-7939 in the  
Prevention of VTE in Patients Undergoing Total Knee Replacement, Bayer, Inc, 2004  
Chairman, Data Safety Monitoring Committee, Phase III Trial of Razaxaban in Orthopedic Surgery,  
Bristol Myers Squibb, 2004  
Chairman, Data Safety Monitoring Board, Phase Ia Trial in Healthy Volunteers of an Aptamer-RNA  
Targeting Factor IXa, 2005-2006  
Advisor, German Patient Self-Management of Oral Anticoagulation Trial, 2004  
Chairman, Data Safety Monitoring Board, Phase 1b Trial in Elderly Cardiac Volunteers of an Aptamer-  
RNA Targeting Factor IXa, 2006-2007  
Chairman, Data Safety Monitoring Board, Phase II trial of Apixaban for DVT Prevention in Cancer  
Patients.  
Chairman, Data Safety Monitoring Board, DVT Prevention with Apixaban in Orthopedic Surgery and in  
Medically Ill patients  
Member, Steering Committee, Phase III trial of Apixaban for Stroke Prevention in Atrial Fibrillation

**Selected CME Activity:**

Presenter, American Society of Hematology Education Sessions – 2000  
Co-Chair, Oral Session, American College Cardiology - 2000  
Abstract reviewer – American Society of Hematology 2002  
Co-Chair, Oral Session, American Society of Hematology, 2002  
NOCR ASH Highlights 2002, 2003, 2004, 2005  
Speakers Bureau,  
DuPont Pharmaceuticals, Aventis, AstraZeneca, Sanofi, Bristol Myers Squibb,  
Roche Diagnostics, International Technidyne, Hemosense  
CME Courses

- 1991 1<sup>st</sup> National Conference on Anticoagulant Therapy, Course Director
- 1993 2<sup>nd</sup> National Conference on Anticoagulant Therapy, Course Director
- 1995 3<sup>rd</sup> National Conference on Anticoagulant Therapy, Course Director
- 1997 4<sup>th</sup> National Conference on Anticoagulant Therapy, Course Director
- 1999 5<sup>th</sup> National Conference on Anticoagulant Therapy, Course Director
- 2001 6<sup>th</sup> National Conference on Anticoagulant Therapy, Course Director
- 2003 7<sup>th</sup> National Conference on Anticoagulant Therapy, Course Director
- 2005 8<sup>th</sup> National Conference on Anticoagulant Therapy, Course Director
- 2007 9<sup>th</sup> National Conference on Anticoagulant Therapy, Course Director
- 2003 The Role of Managed Care in Venous Thromboembolism, Course Director
- 2003 Advancing into a New Era of Anticoagulant Therapy, Course Director
- 2004 Venous Thromboembolism Prevention in the Long-Term Care Setting, Course Director
- 2000 American Society of Hematology Satellite Symposium (sp: AstraZeneca)
- 2001 American Society of Hematology Satellite Symposium (sp: AstraZeneca)
- 2002 American Society of Hematology Satellite Symposium (sp: AstraZeneca)
- 2004 American Society of Hematology Satellite Symposium, (sp: AstraZeneca) Course Director
- 2005 American Society of Hematology Satellite Symposium, (sp: AstraZeneca)
- 2006 American Society of Hematology Satellite Symposium, (sp: Bayer)
- 2006 European Society of Cardiology Satellite Symposium, Moderator and speaker
- 2006 First International Symposium and Workshop: Prevention of Thromboembolic Events: The Role of Point-of-Care Management, Berlin, Germany; Speaker & Session Chair
- 2001 International Society of Thrombosis & Hemostasis Satellite Symposium (sp: AstraZeneca)
- 2003 International Society of Thrombosis & Hemostasis Satellite Symposium (sp: AstraZeneca)
- 2007 International Society of Thrombosis & Hemostasis Satellite Symposium (sp: Bayer) Co-Chair

**SELECTED COMMUNITY ACTIVITIES**

- Leukemia Society of America, Massachusetts Chapter
  - Member, Board of Trustees, 1980 - 1997
  - Chairman, Professional Education Committee, 1990 -
  - Vice President, Massachusetts Chapter LSA, 1996, 1997
- American Cancer Society, Central Massachusetts Chapter
  - Member, Board of Trustees
  - Advisory Board, Hope Lodge of the ACC
- Worcester Community Board of Trustees, United Way
- Board of Directors, Worcester Area Systems for Affordable Health Care, 1982-1986
  - (a business/health coalition operating under a Robert Wood Johnson Foundation Grant to improve health care and decrease cost in Central Massachusetts)
  - Chairman, Community Interest Advisory Council of WASAHC
- Board of Directors, The Caitlin Raymond International Registry of Bone Marrow Donor Banks
- Board of Directors, Worcester Fights Back (WFB, a community coalition funded by a Robert Wood Johnson Foundation Grant to fight substance abuse in the City of Worcester)
- Medical Advisory Board, INNOVA Home Therapies

## **RESEARCH ACTIVITIES**

Over the years my research has focused on the disciplines of Hemostasis and Thrombosis, especially in the areas of Thrombotic Disorders and Antithrombotic Therapy. Although originally involved in basic laboratory research, most of my career has been devoted to clinical trials addressing specific clinical problems or testing new therapeutic agents. I have had a continued interest and involvement in the application of new modes of delivering and monitoring anticoagulants, and particularly in the management of oral anticoagulant therapy. I have played a central role in the concept and promotion of anticoagulation clinics, and guidelines and policies for the management of oral anticoagulation. I have played a key role in the development, testing and validation of point-of-care INR monitoring instrumentation. I have also focused on developing new diagnostic strategies for thrombotic disorders and have conducted a number of multi-institutional clinical trials of antithrombotic agents or agents for the treatment of postoperative hemorrhage. Research support has come from a number of sources, but primarily the pharmaceutical industry.

## ORIGINAL INVESTIGATIONS, REVIEWS, EDITORIALS:

1. **Ansell JE**, Wheby MS. Pica: Its relation to iron deficiency. *Virginia Medical Monthly* 1972; 99:921-954.
2. **Ansell JE**, Kumar R, Deykin D. The spectrum of vitamin K deficiency. *JAMA* 1977; 238:40-42.
3. Johnson WC, Widrich WC, **Ansell JE**, Robbins AH, Nabseth DC. Control of bleeding varices by vasopressin: A prospective randomized study. *Ann Surg* 1977; 186:369-376.
4. **Ansell JE**, Widrich WC, Johnson WC, Robbins AH, Nabseth DC, Deykin D. Gelfoam and autologous clot embolization: Its effect on coagulation. *Invest Rad* 1978; 13:115-120.
5. Kumar R, **Ansell J**, Canoso RT, Deykin D. Clinical trial of a new bleeding time device. *Amer J Clin Path* 1978; 70:642-645.
6. **Ansell J**, Beaser R, Pechet L. Thrombotic thrombocytopenic purpura fails to respond to fresh frozen plasma infusion. *Ann Intern Med* 1978; 89:647-648.
7. **Ansell J**, Slepchuk N, Kumar R, Lopez A, Southard L, Deykin D. Heparin induced thrombocytopenia: A prospective study. *Thrombo Hemostas* 1980;43:61-65.
8. **Ansell J**, Deykin D. Heparin induced thrombocytopenia and recurrent thromboembolism. *Am J Hematol* 1980; 8:325-332.
9. **Ansell J**, Bhawan J, Pechet L. Leukemia cutis in blastic transformation of chronic myelocytic leukemia: TDT positive blasts and response to vincristine and prednisone. *J Cutaneous Path* 1980; 7:302-309.
10. Spiro R, **Ansell J**, Katayama I, Muralidharan K, Sullivan J, Humphreys R.. Differences in synthesis of membrane proteins by leukemic cells from spleen and peripheral blood indicate distinct subsets of malignant cells in a patient with prolymphocytic leukemia. *Am J Hematol* 1981; 11:261-270.
11. Parilla N, **Ansell J**. Anticoagulation by constant subcutaneous heparin infusion. *Thrombos Hemostas* 1982; 47:1-2.
12. Layne WW, Hnatowich DJ, Doherty PW, Childs R, Lanteigne D, **Ansell J**. Evaluation of the viability of In-111-labeled DTPA coupled to fibrinogen. *J Nuc Med* 1982; 23:627-630.
13. **Ansell J**, Parilla N, King M, Fournier L, Szymanski I, Doherty P, VanderSalm T, Cutler B. Survival of autotransfused red blood cells recovered from the surgical field during cardiovascular surgery. *J Thorac Cardiovas Surg* 1982; 84:387-391.
14. **Ansell J**, Bhawan J, Cohen S, Sullivan J, Sherman D. Histiocytic lymphoma and malignant angioendotheliomatosis: One disease or two? *Cancer* 1982; 50:1506-1512.
15. **Ansell JE**, Tiarks Cy, McCue JE, Parilla N, Benotti, JR. Amrinone induced thrombocytopenia *Arch Intern Med* 1984; 144:949-952.
16. Errichetti AM, Holden A, **Ansell J**. Managing oral anticoagulant therapy: Experience with an anticoagulation clinic. *Arch Intern Med* 1984; 144:1966-1968.
17. Badon S, Coslovsky R, Gill L, **Ansell J**, Woda B. Diabetes insipidus caused by extramedullary hematopoiesis. *Am J Clin Path* 1985; 83:509-512.17.

18. **Ansell J**, Price J, Shah S. Heparin-induced thrombocytopenia: What is its real frequency? *Chest* 1985; 88:878-882.
19. Hitzhusen J, Taplin ME, **Ansell J**. Vitamin B<sub>12</sub> levels and age. *Am J Clin Pathol* 1986; 85:32-36.
20. **Ansell J**, VanderSalm T, Stephenson W, Szymanski I, Fournier L. In vivo survival of red blood cells processed by a bubble or membrane oxygenator during cardiopulmonary bypass surgery. *Texas Heart Institute Journal* 1986; 13:247-251.
21. Krauth D, Holden A, Knapic N, Liepman M, **Ansell J**. Long term anticoagulation in patients with cancer. *Cancer* 1987; 59:983-985.
22. Daum GS, Sullivan JL, **Ansell J**, Mulder C, Woda B. Virus associated hemophagocytic syndrome: Identification of an immunoproliferative precursor lesion. *Hum Pathol* 1987; 18:1071-1074.
23. **Ansell J**. Hypercoagulability: A conceptual and diagnostic approach. *Am Heart J* 1987; 114:910-913.
24. Hnatowich D, Virzi F, Doherty P, Rosa J, **Ansell J**. In vitro and in vivo characterization of indium-111 labeled recombinant tissue plasminogen activator for the imaging of thrombi. *Eur J Nucl Med* 1987; 13:467-473.
25. VanderSalm TJ, **Ansell JE**, Okike ON, Marsicano TH, Lew R, Stephenson WP, Rooney K. The role of epsilon amino caproic acid in reducing bleeding after cardiac operation: A double blind randomized study. *J Thor Cardiovas Surg* 1988; 95:538-540.
26. Gurwitz J, Goldberg R, Holden A, Knapic N, **Ansell J**. Age-related risks of long-term oral anticoagulant therapy. *Arch Int Med* 1988; 148:1733-1736.
27. **Ansell J**. The Medical Society ... Who needs it. *Worcester Medical News* 1988;53:3.
28. **Ansell J**, Hamke K, Holden A, Knapic N. Cost effectiveness of monitoring warfarin therapy using standard versus capillary prothrombin times. *Amer J Clin Pathol* 1989; 91:587-589.
29. **Ansell J**. Hand me the paddles, please. *Worcester Medical News* 1989; 54:3-4.
30. Stone S, Holden A, Knapic N, **Ansell J**. Comparison between videotape and personalized patient education for anticoagulant therapy. *J Fam Pract* 1989; 29:55-57.
31. **Ansell J**, Holden A, Knapic N. Patient self-management of oral anticoagulation guided by capillary (fingerstick) whole blood prothrombin times. *Arch Intern Med* 1989; 149:2509-2511.
32. Cola C, **Ansell J**. Heparin induced thrombocytopenia: Alternative therapies. *Amer Heart J* 1990; 119:368-374.
33. **Ansell J**. Straddling the decades: A look back--a look ahead. *Worcester Medicine* 1990;55:25-29.
34. **Ansell J**, Tiarks C, Hirsh J, McGehee W, Adler D, Weibert R. Measurement of the activated partial thromboplastin time from a capillary (fingerstick) sample of whole blood: A new method of monitoring heparin therapy. *Amer J Clin Pathol* 1991; 95:222-227.
35. Harrington R, **Ansell J**. Risk benefit assessment of anticoagulant therapy. *Drug Safety* 1991; 6:54-69.
36. Becker RC, Corrao JM, Ball SP, Klassen V, Baker SP, **Ansell J**. The impact of intravascular thrombus formation on hemorrhagic complications following recombinant tissue-type plasminogen activator administration. *J Appl Cardiol* 1991;6:221-227.

37. **Ansell JE.** Hematologic emergencies for the cardiovascular specialist. *Cardio* 1991; 8:51-58.
38. Li JM, Menconi MJ, Klassen VA, Rohrer MJ, **Ansell JE**, Wheeler HB. Thrombomodulator production by human saphenous and umbilical vein endothelial cells in culture. *J Vasc Med Biol* 1991; 3:124-133.
39. Harrington R, **Ansell J.** Trends in antithrombotic therapy. *J Am Acad Phys Assist* 1992;5:131-141.
40. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovsky I, **Ansell J.** Aging and the anticoagulant response to warfarin therapy. *Ann Intern Med* 1992; 116:901-904.40.
41. **Ansell J**, Holden A, Nozzolillo E. Oral Anticoagulant therapy: Practical considerations. *Nurse Practitioner Forum* 1992; 3:1-8.
42. Li JM, Menconi MJ, Wheeler HB, Rohrer MJ, Klassen VA, **Ansell J**, Appel MC. Precoating expanded polytetrafluoroethylene alters production of endothelial cell-derived thrombo-modulators. *J Vasc Surg* 1992; 15:1010-1017.
43. **Ansell JE.** It's time to lead the way. *Worcester Medicine* 1992; 58:32.
44. **Ansell J**, Klassen V, Lew R, Ball S, Weinstein M, VanderSalm T, Gratz I, Roberts A, Leslie J, Fleming N. A randomized, double-blind study of the efficacy and safety of Desmopressin to reduce hemorrhage following cardiac surgery. *J Thor Cardiovas Surg* 1992; 104:117-123.
45. **Ansell J.** Imprecision of prothrombin time monitoring of oral anticoagulation: A survey of hospital laboratories. *Am J Clin Pathol* 1992; 98:237-239.
46. **Ansell JE**, Tiarks C, Fairchild VK. Coagulation abnormalities associated with the use of anabolic steroids. *Am Heart J* 1993; 125:367-371.
47. **Ansell J.** Oral anticoagulant therapy: Fifty years later. *Arch Int Med* 1993;153:586-596.
48. Maher VE, Gill L, Townes PL, Wallace JE, Savas L, Woda BA, **Ansell JE.** Simultaneous chronic lymphocytic leukemia and chronic myelogenous leukemia: Evidence of a separate stem cell origin. *Cancer* 1993; 71:1993-1997.
49. Becker RC, **Ansell J.** Cardiovascular effects of anabolic steroids. *Primary Cardiology* 1994;20:26-27.
50. Chaturvedi S, **Ansell J**, Recht L. Should cerebral ischemic events in cancer patients be considered a manifestation of Trousseau's syndrome. *Stroke* 1994;25:1215-1218.
51. Spiro TE, Johnson GJ, Christie MJ, Lyons RM, MacFarlane DE, Blasier RB, Tremaine MD, and the Enoxaparin Clinical Trial Group. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement. *Ann Intern Med* 1994; 121:81-89.
52. **Ansell J.** The future of medicine is here today. *Worcester Medicine* 1994; 60:3-4.
53. Becker R, **Ansell J.** Antithrombotic therapy: An abbreviated clinicians reference. *Arch Intern Med* 1995; 155:149-161.
54. **Ansell JE**, Patel N, Ostrovsky, Nozzolillo E, Peterson AM, Fish L. Long-term patient self-management of oral anticoagulation. *Arch Intern Med* 1995; 155:2185-2189.
55. Berenson JR, Lichtenstein A, Porter L, et al. for the Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. *N Engl J Med* 1996; 334:488-493.

56. Leaning KE, **Ansell JE**. Advances in the monitoring of oral anticoagulation: Point-of-care testing, patient self-monitoring, and patient self-management. *J Thromb Thrombolys* 1996; 3:377-383.
57. **Ansell JE**, Hughes R. Evolving models of warfarin management: Anticoagulation clinics, patient self-monitoring and patient self-management. *Amer Heart J* 1996;132:1095-1100.
58. Becker RC, **Ansell J**. The need for long-term anticoagulants in venous thromboembolism: How Long? *Clin Appl Thrombosis/Hemostasis* 1997;3(Suppl.1):S8-S14.
59. **Ansell JE**, Buttaro ML, Voltis-Thomas O, Knowlton C. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. *Ann Pharmacother* 1997; 31:604-615.
60. **Ansell JE**. Anticoagulation management as a risk factor for adverse events: Grounds for improvement. *J Thromb Thrombolys* 1998;5(suppl)(S13-S18).
61. **Ansell JE**. Anticoagulation management clinics for the out-patient control of oral anticoagulants. *Current Opinion Pulmonary Med* 1998;4:215-219.
62. Fairweather RB, **Ansell J**, van den Besselaar AMHP, Brandt JT, Bussey HI, Poller L, Triplett DA, White RH. Laboratory monitoring of oral anticoagulant therapy. *Arch Pathol Lab Med* 1998; 122:768-781.
63. Hirsh J, Dalen JE, Anderson D, Poller L, Bussey HI, **Ansell JE**, Deykin D, Brandt JT. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. *Chest* 1998;114(Suppl):445S-469S.
64. **Ansell JE**. Anticoagulation, Acute and Chronic: Indications and methods. *Current Practice of Medicine* 1998;1:675-684.
65. **Ansell JE**. Empowering patients to monitor and manage oral anticoagulation therapy. *JAMA* 1999;281:182-183.
66. **Ansell JE**. Out-of-hospital coagulation monitoring and management. *J Thrombo Thrombolys* 1999;7:191-194.
67. McCormick D, Gurwitz JH, Goldberg RJ, **Ansell J**. Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk and current patterns of use. *J Thromb Thrombolys* 1999;7:157-164.
68. Sickles J, Elston-Lafata J, **Ansell J**. Point-of-care testing in coagulation and haemostasis: Implications for patient management. *Dis Manage Health Outcomes* 1999;6:291-301.
69. **Ansell J**. The quality of anticoagulation management. *Arch Intern Med* 2000;160:895-896.
70. **Ansell JE**, Weitz JI, Comerota AJ. Advances in therapy and the management of antithrombotic drugs for venous thromboembolism. *Blood* 2000;96:266-284
71. **Ansell J**, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, Jacobson A, Deykin D, Matchar D. Managing oral anticoagulant therapy. *Chest* 2001; 119:22S-38S.
72. Hirsh J, Dalen J, Anderson, Poller L, Bussey H, **Ansell J**, Deykin D, Brandt J. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. *Chest* 2001; 119:8S-21S.

73. Oral Anticoagulation Monitoring Study Group. Point-of-care prothrombin time measurement for professional and patient self-testing use. A multicenter clinical experience. *Amer J Clin Pathol* 2001;115:288-296.
74. Oral Anticoagulation Monitoring Study Group. Prothrombin measurement using a patient self-testing system. *Amer J Clin Pathol* 2001;115:280-287.
75. **Ansell JE.** Air travel and venous thromboembolism – Is the evidence in? *N Engl J Med* 2001;345:828-829.
76. Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, Peters G, for the AstraZeneca Arthroplasty Study Group. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. *Arch Intern Med* 2001;161:2215-2221.
77. **Ansell, JE.** Patient Self-Testing and Patient Self-Management of Oral Anticoagulation: Is It Too Late? *Israeli Medical Journal* 2002;4:1035-1036
78. Hirsh J, Fuster V, **Ansell J**, Halperin JL. AHA/ACC Foundation Guide to Warfarin Therapy. *JACC* 2003;41:1633-1652.
79. **Ansell JE.** The perioperative management of warfarin therapy. *Arch Intern Med* 2003;163:881-883.
80. **Ansell JE.** Optimizing the Efficacy and Safety of Oral Anticoagulant Therapy: High Quality Dose Management, Anticoagulation Clinics, and Patient Self-Management. *Semin Vas Med* 2003;3:261-269.
81. Palareti G, **Ansell J**, Baglin T (Guest Editors). Oral Anticoagulation in Clinical Medicine for Venous and Arterial Thrombotic Indications. *Semin Vas Med* 2003;3:215-344.
82. Andrea N, **Ansell J.** Antithrombotic therapy in patients with cancer. *Supportive Oncology* 2003;1:1-7.
83. Schmitt L, Speckman J, **Ansell J.** Quality assessment of anticoagulation dose management: Comparative evaluation of measures of time-in-therapeutic range. *J Thromb Thrombolys* 2003;15:213-216.
84. **Ansell J**, Hasenkam JM, Voller H, Jacobson A, Levy J. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. *Internat J Cardiology* 2004;99:37-45
85. **Ansell J.** Aktuelle herausforderungen im management von thromboembolischen erkrankungen (Current challenges in the management of thromboembolic disease). *Vasomed* 2004;3:102-103.
86. **Ansell J.** New anticoagulants and their potential impact on the treatment of thromboembolic disease. *Curr Heme Reports* 2004;3:357-362.
87. **Ansell J.** Long-term secondary treatment of deep venous thrombosis: Do we know the appropriate duration of treatment or therapeutic regimen? *Curr Heme Reports* 2004;3:355-356.
88. **Ansell J**, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists. *Chest* 2004;126(Suppl):202S-231S.
89. Nutescu EA, Pickard AS, Blackburn JC, Wittkowsky A, **Ansell J**, Schumock GT. Potential implications of oral direct thrombin inhibitors for anticoagulation clinics. *Pharmacotherapy* 2004;24:1204-1212

90. Oran B, Lee-Parritz A, **Ansell J**. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. *Thromb Haemost* 2004;92:747-751.
91. **Ansell J**, Bergqvist D. Current options in the prevention of thromboembolic disease. *Drugs* 2004;64(Suppl 1):1-5.
92. Ansell JE. Emerging therapies in anticoagulation. *Managed Care* 2004;9(Supplement):8-12.
93. Blanchard E, **Ansell J**. Extended anticoagulant therapy for the primary and secondary prevention of venous thromboembolism. *Drugs* 2005;65:303-311.
94. Wittkowsky AK, Sekreta CM, Nutescu EA, **Ansell J**. Barriers to patient self-testing of prothrombin time: national survey of anticoagulation practitioners. *Pharmacotherapy*.2005;25(2):265-9.
95. **Ansell J**. Oral anticoagulants-the old and the new. *Disease-a-Month* 2005;51:208-212.
96. **Ansell J**. Long-term anticoagulants: The prospects for alternatives to warfarin. *Semin Vas Surg* 2005;18:134-138.
97. Matchar DB, Jacobson AK, Edson RG, Lavori PW, **Ansell JE**, Ezekowitz MD, Rickles F, Fiore L, Boardman K, Phibbs C, Fihn SD, Vertrees JE, Dolor R. The impact of patient self-testing of prothrombin time for managing anticoagulation: Rationale and design of VA Cooperative Study #481 – The Home INR Study (THINRS). *J Thromb Thrombolys* 2005;19:163-172
98. **Ansell J**. Is self-management of oral anticoagulation a feasible and safe option? *Nature Clin Practice* 2005;2:240-241.
99. **Ansell J**. Vena Cava Filters: Do we know all that we need to know? *Circulation* 2005;112:298-299.
100. **Ansell J**. Long-term follow-up of patients with vena cava filters for the prevention of pulmonary embolism. *Curr Hemat Rep* 2005;4:375-377.
101. Battinelli EM, **Ansell J**. Cancer and thrombosis. *Curr Hemat Rep* 2005;4:378384.
102. **Ansell J**. Effects of dietary supplements on hemostasis. *Thromb Res* 2005;117:45-47.
103. Blanchard E, **Ansell J**. Extreme factor IX sensitivity to warfarin. *Clin Adv Hematol Oncol* 2005;4:1-3.
104. Dinwoodey DL, **Ansell JE**. Heparins, Low Molecular Weight Heparins, and Pentasaccharides. *Clinics in Geriatric Medicine* 2006;22(1): 1-15.
105. Weichman, K, **Ansell J**. Inferior venal cava filters in venous thromboembolism. *Prog Cardiovas Dis* 2006;49:98-105
106. Aguilar MI, Hart RG, Kase CS, Freeman WD, Hoeben BJ, Garcia RC, Ansell JE, et al. Treatment of warfarin-associated intracerebral hemorrhage: Survey of the literature and expert recommendations. *Mayo Clinic Proceedings* 2007;82:82-92
107. **Ansell J**, Hollowell J, Pengo V, Martinez-Brotos F, Caro J, Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the International study of anticoagulation management (ISAM): *J Thromb Thrombly* 2007;23:83-91

108. **Ansell J**, Caro J, Salas M, Dolor R, Corbett W, Hudnut A, Seyal S, Lordan N, Proskorovsky I, Wygant G. The quality of anticoagulation control in routine medical care of patients with chronic non-valvular atrial fibrillation in the United States. *Amer J Med Qual* 2007;22:327-333
109. **Ansell J**. Factor Xa or thrombin: is factor Xa a better target? *J Thromb Haemost* 2007;5(Suppl.1):1-5.
110. Lassen MR, Davidson BL, Gallus A, Pineo G, **Ansell J**, Deitchman D. The efficacy and safety of apixaban, an oral direct factor Xa inhibitor, as thromboprophylaxis in patients following total hip replacement. *J Thromb Haemost* 2007;5:1-8 (in press)
111. **Ansell J**. Recommendations on bleeding and nonbleeding complications of vitamin K antagonists. *Clin Adv Hemat Oncol* 2007;5:517
112. Taborski U, Voller H, Hartwig I, Kadar J, Dovifat C, Wegfscheider K, Zucker ML, LaDuca FM, **Ansell J**. The German paradigm for oral anticoagulation patient self-management as implemented using the ProTime system. *Thromb Haemost* 2007; (in press)
113. Phillips K, **Ansell J**. The Outpatient Management of Oral Vitamin K Antagonist Therapy: Defining and Measuring High Quality Management. *Exp Rev Cardiovas Therap* 2007; (in press)
114. **Ansell, J**, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. The pharmacology and management of the vitamin K antagonists: ACCP evidence-based clinical practice guidelines. *Chest* 2008; (in press).
115. Douketis JD, Becker RC, Berger P, Dunn AS, Jaffer AK, Spyropoulos AC, **Ansell J**. Perioperative management of antithrombotic therapy: ACCP evidence-based clinical practice guidelines. *Chest* 2008; (in press).
116. Dinwoodey DL, **Ansell JE**. Heparins, Low Molecular Weight Heparins, and Pentasaccharides. *Clinics in Cardiology* 2008 (in press).
117. Ansell J. Anticoagulation Monitoring: Point of care vs lab – It’s time to embrace today’s technology. *Group Practice Journal* 2008 (in press)
118. Ansell J, McDonough ME, Harmatz JS, Greenblatt DJ. The absences of an interaction between warfarin and cranberry juice: a randomized, double-blind trial (in preparation)

## BOOKS, CHAPTERS, VIDEOS, ETC:

1. Kumar R, **Ansell J**, Deykin D. Clinical trial of a new bleeding time device. The Significance of Platelet Function Tests in the Evaluation of Hemostatic and Thrombotic Tendencies. HJ Holmsen and MB Zucker (eds). DHEW Pub No. (NIH) 77-1087, pp. 21-22, 1977.
2. **Ansell J**, Levine P. Anticoagulant management in patients with valvular heart disease. Valvular Heart Disease. J Dalen and J Alpert (eds). Little Brown & Co., Boston (1<sup>st</sup> Edition 1982, 2<sup>nd</sup> Edition 1987).
3. **Ansell J**. Pathologic bleeding. Signs and Symptoms. R Blacklow (ed). J.B. Lippincott Co., Philadelphia (6<sup>th</sup> Edition), 1983.
4. **Ansell J**. Hematology Section Editor. Intensive Care Medicine. JM Rippe, RS Irwin, JS Alpert, JE Dalen (eds). Little Brown & Co., Boston (2<sup>nd</sup> Edition, 1991, 3<sup>rd</sup> Edition, 1995, 4<sup>th</sup> Edition 1999).
5. **Ansell J**. Acquired coagulopathies. Intensive Care Medicine. JM Rippe, RS Irwin, JS Alpert, JE Dalen (eds). Little Brown & Co., Boston (1<sup>st</sup> Ed, 1985, 2<sup>nd</sup> Ed, 1991, 3<sup>rd</sup> Ed, 1995, 4<sup>th</sup> Ed 1999).
6. **Ansell J**, Levine P. Anticoagulant therapy. Intensive Care Medicine. JM Rippe, RS Irwin, JS Alpert, JE Dalen (eds). Little Brown & Co., Boston (1<sup>st</sup> Ed, 1985, 2<sup>nd</sup> Ed 1991, 3<sup>rd</sup> Ed, 1995, 4<sup>th</sup> Ed 1999).
7. **Ansell J**. Handbook of Hemostasis and Thrombosis: A Diagnostic Approach. Little Brown & Co., Boston, 1986.
8. **Ansell J**. Hematology Section Editor. Textbook of General Medicine and Primary Care. J Noble (ed). Little Brown & Co., Boston, 1987.
9. **Ansell J**. Hematopoiesis. Textbook of General Medicine and Primary Care. J Noble (ed). Little Brown & Co., Boston, 1987.
10. **Ansell J**. Approach to anemia. Textbook of General Medicine and Primary Care. J Noble (ed). Little Brown & Co., Boston, 1987.
11. **Ansell J**. White blood cell disorders. Textbook of General Medicine and Primary Care. J Noble (ed). Little Brown & Co., Boston, 1987.
12. **Ansell J**. Thromboembolic disorders. Textbook of General Medicine and Primary Care. Little Brown & Co., Boston, 1987.
13. **Ansell J**, Holden A, Knapic N, Rezuze L. A Patient's Introduction to Anticoagulant Therapy. (A patient education videotape)
14. Cola C, **Ansell J**. Platelet-mediated bleeding disorders. Conn's Current Therapy. R Rakel (ed). WB Saunders Co., Philadelphia, 1990.
15. **Ansell J**. Section Editor. Introduction to Clinical Medicine. H Green, R Glasscock, M Kelly (eds). BC Decker, Inc., Philadelphia, (1<sup>st</sup> Edition, 1991, 2<sup>nd</sup> Edition, 1994).
16. **Ansell J**. Anemia. Introduction to Clinical Medicine. H Green, R. Glasscock, M Kelly (eds). BC Decker, Inc., Philadelphia, (1<sup>st</sup> Edition, 1991, 2<sup>nd</sup> Edition, 1994).
17. **Ansell J**. Thromboembolic disease. Introduction to Clinical Medicine. H Green, R Glasscock, M Kelly (eds). BC Decker, Inc., Philadelphia, (1<sup>st</sup> Edition, 1991, 2<sup>nd</sup> Edition, 1994).

18. Cola C, **Ansell J**. Autoimmune hemolytic anemia. Conn's Current Therapy. R Rakel (ed). WB Saunders Co., Philadelphia, 1991.
19. **Ansell J**. The blood in hyperthyroidism. The Thyroid. SH Ingbar, LE Braverman (eds). J.B. Lippincott Co., Philadelphia, (1<sup>st</sup> Ed, 1991, 2<sup>nd</sup> Ed, 1996).
20. **Ansell J**. The blood in hypothyroidism. The Thyroid. SH Ingbar, LE Braverman (eds). J.B. Lippincott Co., Philadelphia, (1<sup>st</sup> Ed, 1991, 2<sup>nd</sup> Ed, 1996).
21. Nardella A, **Ansell J**. Understanding and implementing the international normalized ratio for reporting prothrombin time results. Tech Sample 1993; No. H-5.
22. **Ansell J**. Practical guidelines for the use and monitoring of warfarin. Am J Medicine Continuing Education Series, J Dalen (ed). Part III, 1994.
23. Proceedings of the Third National Conference on Anticoagulation Therapy. Editor, **J. Ansell**. J Thrombo Thrombolysis 1995; 2:261-325.
24. **Ansell J**. Hematology/Oncology Section Editor. Primary Care and General Medicine. Mosby Year Book, 1996.
25. **Ansell J**. Cardinal Manifestations of Hematologic Disease, in Primary Care and General Medicine. Mosby Year Book, 1996.
26. **Ansell J**, Thane M. Hemorrhagic and Thrombotic Disorders, in Primary Care and General Medicine. Mosby Year Book, 1996.
27. **Ansell J**. Oral anticoagulants in the treatment of venous thromboembolism. Disorders of Thrombosis. R Hull, G Pineo (eds). W.B. Saunders & Co. Philadelphia. 1996.
28. Becker R, **Ansell J**. Oral anticoagulants (antithrombotic agents) for cardiovascular disorders. Disorders of Thrombosis. R Hull, G. Pineo (eds). W.B. Saunders & Co. Philadelphia. 1996.
29. **Ansell J**. Oral Anticoagulants Therapy. Venous Thromboembolism: An Evidence-Based Atlas. RH Hull, G Raskob, G Pineo, (eds). Futura Publishing. New York. 1996.
30. Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines. **J Ansell**, L Oertel, A Wittkowsky (eds). Aspen Publishing Inc. Maryland, 1997.
31. **Ansell J**. Historical developments in oral Anticoagulation. Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines. J Ansell, L Oertel, A Wittkowsky (eds). Aspen Publishing Inc. Maryland, 1997.
32. **Ansell J**. The value of an anticoagulation management service. Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines. J Ansell, L Oertel, A Wittkowsky (eds). Aspen Publishing Inc. Maryland, 1997.
33. **Ansell J**, Voltis Thomas O. Guidelines for development of an anticoagulation management service. Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines. J Ansell, L Oertel, A Wittkowsky (eds). Aspen Publishing Inc. Maryland, 1997.
34. Leaning K, **Ansell J**. Capillary whole blood prothrombin time monitoring: Instrumentation and methodologies. Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines. J Ansell, L Oertel, A Wittkowsky (eds). Aspen Publishing Inc. Maryland, 1997.

35. **Ansell J.** Evaluation and management of excessive anticoagulation and bleeding. Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines. J Ansell, L Oertel, A Wittkowsky (eds). Aspen Publishing Inc. Maryland, 1997.
36. **Ansell J.** Managing surgery and other invasive procedures. Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines. J Ansell, L Oertel, A Wittkowsky (eds). Aspen Publishing Inc. Maryland, 1997.
37. **Ansell J.** Point-of-care testing: Patient self-testing and patient self-management. Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines. J Ansell, L Oertel, A Wittkowsky (eds). Aspen Publishing Inc. Maryland, 1997.
38. Szymanski IO, **Ansell JE**, Vander Salm T. Effect of Blood Salvage on Red Cell Survival. in Autotransfusion: Therapeutic Principles and Trends. RL Tawes Jr., (ed). Gregory Appleton, Detroit, 1997.
39. Proceedings of the Fourth National Conference on Anticoagulation Therapy. Editor, **J. Ansell. J** Thrombo Thrombolys 1998; 5(Suppl 1):S7-S75.
40. **Ansell JE.** Section Editor, Hematology/Oncology. in Decision Making in Medicine. HL Greene, WP Johnson, D Lemcke (eds). Mosby Year Book, Inc, St. Louis, 1998.
41. **Ansell JE.** Oral Anticoagulants for the Treatment of Venous Thromboembolism. in Prevention, Diagnosis and Management of Venous Thromboembolic Disease. G Pineo, R Hull (eds). Bailliere Tindall/WB Saunders, London. 1999.
42. **Ansell JE**, Hickey AD, Kleinschmidt KC, Merli GJ, Tillman DJ, Yusen RD. Advancing the treatment of deep venous thrombosis and pulmonary embolism. Guidelines for inpatient and outpatient therapy with enoxaparin. Sci-Health Communications, Cincinnati OH; a CME brochure sponsored by Aventis Pharmaceuticals. March 2000.
43. **Ansell JE**, Becker RC. Coordinated Anticoagulation Services and Home Management Programs, in Cardiovascular Medicine, Practice and Management, RC Becker, JS Alpert (eds). Arnold Publishing, New York, 2001.
44. Proceedings of the Fifth National Conference on Anticoagulation Therapy. Editor, **J. Ansell. J** Thrombo Thrombolys 2000; 9(Suppl 1):S7-S75.
45. Harrington RA, **Ansell JE**, Weitz JI. Improving long-term antithrombotic therapy for ischemic heart disease and atrial fibrillation. Institute for Continuing Healthcare Education and Concepts Technologies; A CME brochure sponsored by AstraZeneca Pharmaceuticals, October 2001.
46. **Ansell JE.** Anticoagulation, Acute and Chronic: Indications and Methods, in Cardiology for the Primary Care Physician, 3<sup>rd</sup> Ed, JS Alpert, ed., Current Medicine, Philadelphia, 2001
47. Proceedings of the Sixth National Conference on Anticoagulation Therapy. Editor, **J. Ansell. J** Thrombo Thrombolys 2001; 12(Suppl 1):S5-S114.
48. **Ansell JE.** Outpatient Anticoagulant Therapy, in Consultative Hemostasis and Thrombosis. C Kitchens, B Alving, C Kessler (eds). Harcourt Health Sciences, New York, 2002 (in press).
49. **Ansell JE.** Patient self-testing and self-management of oral anticoagulation with point-of-care testing, in Principles & Practice of Point-Of-Care Testing GJ Kost (ed). Lippincott Williams & Wilkins, Philadelphia, 2002.

50. Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines. **J Ansell**, L Oertel, A Wittkowsky (eds). **2<sup>nd</sup> Ed.** Aspen Publishing Inc. Maryland, 2003.
51. Joist JH, **Ansell JE**, Despotis GG, LaDuca F, Marlar RA, Michaud GY, Phillips DL, Santrach PJ. Point-of-care monitoring of anticoagulation therapy: Proposed guideline. NCCLS document H49-P;2003; Vol 23:1-21 (ISBN 1-56238-505-4).
52. **Ansell, J.** Venous Thromboembolism, in Peripheral Vascular Disease, M Creager, J Loscalzo (eds), **2<sup>nd</sup> Ed.** Elsevier Science, Philadelphia, 2005.
53. **Ansell, J.** Thrombotic Disorders, Section Editor. *Current Hematology Reports* 2004;3:355-388.
54. Proceedings of the Seventh National Conference on Anticoagulation Therapy. Editor, **J. Ansell.** *J Thrombo Thrombolys* 2003; 16:5-109.
55. **Ansell, J.** Thrombotic Disorders, Section Editor. *Current Hematology Reports* 2005;4:335-413.
56. **Ansell JE.** Anticoagulation, Acute and Chronic: Indications and Methods, in Cardiology for the Primary Care Physician, **4<sup>rd</sup> Ed**, JS Alpert, ed., *Current Medicine*, Philadelphia, 2005, p 407-418.
57. Proceedings of the Eighth National Conference on Anticoagulation Therapy. Editor, **J. Ansell.** *J Thrombo Thrombolys* 2006;21:7-115
58. Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines. **J Ansell**, L Oertel, A Wittkowsky (eds). Third Edition, Facts & Comparisons Publishing Inc. Missouri, 2008 ( in preparation).
60. Medical Knowledge Self-Assessment Program 15 (MKSAP). **J Ansell**, ed. American College of Physicians, Philadelphia, 2008 (in preparation)

## ABSTRACTS, LETTERS, BRIEF REPORTS, ETC:

1. **Ansell J**, Brauer MJ. Hypersplenism and agranulocytosis: Immune basis unresolved. *Clin Res* 1975; 23:268a.
2. Fine J, Deykin D, **Ansell J**, Hutton R. Limulus test. *N Engl J Med* 1976; 294:48.
3. **Ansell J**, Widrich W, Johnson W, Fine J. Endotoxin and bacteria in portal blood. *Gastroenterology* 1977; 73:1190.
4. **Ansell J**. Aspirin for prophylaxis of venous thromboembolism. *N Engl J Med* 1978; 298:1090-1091.
5. **Ansell J**, Kumar R, Lopez A, Southard L, Deykin D. Delayed onset heparin associated thrombocytopenia. *Blood* 1978; 52 (Suppl. 1):177.
6. **Ansell J**, Tiarks C, Sternthal E. Procainamide-induced systemic lupus erythematosus with lupus-like coagulation inhibitor. *Blood* 1978; 52 (Suppl.1):157.
7. **Ansell J**, Slepchuk N, Pechet L. Thrombotic thrombocytopenic purpura. *Blood* 1979; 54:959-960.
8. **Ansell J**. Jocelyn. *Death Education*. 1981; 5:197-198.
9. Marsland T, Griffin T, **Ansell J**, Hunter R. Control of intra-peritoneal hemorrhage with antifibrinolytic therapy in a patient with ovarian carcinoma. *Thrombo Hemostas* 1981; 46:566.
10. Parilla N, **Ansell J**. Anticoagulation by continuous subcutaneous heparin infusion. *Clin Res* 1981; 29:673A.
11. **Ansell J**, McCue J, Tiarks C, Parilla N, Rybak ME, Benotti J. Amrinone-induced thrombocytopenia. *Blood* 1982; 58(Suppl. 1):187A.
12. Hnatowich DJ, Virzi F, Doherty P, **Ansell J**. Indium-111 labeled tissue plasminogen activator. *J Nuc Med*.
13. **Ansell J**, Doherty PW, Virzi F, Hnatowich DJ. Indium-111 recombinant tissue plasminogen activator for imaging thrombo-emboli.. *Thromb Hemost* 1985; 54:223.
14. **Ansell J**, Errichetti AM, Holden A. Spontaneous retroperitoneal hemorrhage during oral anticoagulant therapy. *Arch Int Med* 1985; 145:1534.
15. **Ansell J**, Clark WP, Compton CC. Fatal reactions associated with intravenous heparin. *Drug Intelligence and Clinical Pharmacy* 1986; 20:74.
16. Gurwitz J, Goldberg R, **Ansell J**. Age related risks of long-term oral anticoagulant therapy. *Clin Res* 1987; 35:743A.
17. Gurwitz J, Goldberg R, **Ansell J**. Age related risks of long-term oral anticoagulant therapy. *Am Ger Soc* 1987.
18. **Ansell J**, Fleury V, Wilson J, Maraganore J. In vitro/in vivo anticoagulant and pharmacokinetic properties of hirugen. *Blood* 1988; 72(Suppl. 1):362A.\*18.
19. Tiarks C, **Ansell J**, Hirsh J, McGehee W. Comparability of fingerstick vs plasma aPTT with a new device for monitoring heparin therapy. *Circulation* 1989; 11:647.
20. **Ansell J**, Klassen V, Lew R, Ball S, Weinstein M, VanderSalm T, Okike N, Gratz I, Leslie J, Roberts A,

- Fleming N, Salzman P. Does DDAVP prophylaxis reduce blood loss after valvular heart surgery? *Blood* 1990; 76:411a.
21. Becker R, Corrao J, Ball S, Klassen V, **Ansell J**. The risk of hemorrhagic complications following rt-PA administration is not influenced by thrombus. *Blood* 1990; 76:499a.
  22. Gurwitz JH, Avorn J, Ross-Degnan D, **Ansell J**. Age-related changes in warfarin pharmacodynamics. *J Clin Pharmacol Ther* 1991; 166.
  - \*23. Spiro TE and Enoxaparin Clinical Trial Group. A randomized trial of Enoxaparin administered postoperatively for the prevention of deep vein thrombosis following elective hip replacement surgery. *Thrombo Hemostas* 1991; 65:927.
  24. **Ansell, J**. Oral Anticoagulant Drugs. *N Engl J Med* 1992; 326:68.
  25. Gurwitz JH, **Ansell J**. Aging and warfarin therapy. *Ann Int Med* 1992; 117:879.
  26. Becker R, Caputo R, Ball S, Corrao J, **Ansell J**. Hemorrhagic Potential of Combined Intravenous Diltiazem and Tissue Plasminogen Activator Administration. *J Amer Coll Cardiol* 1993; 21:39.
  27. Godwin JE, Comp P, Davidson B, Rossi M, Normiflo Cancer Clinical Trial Group. Comparison of the efficacy and safety of subcutaneous RD Heparin versus subcutaneous unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal or pelvic surgery for cancer. *Thromb Hemostas* 1993; 69:647.
  28. **Ansell J**, Becker D, Andrew, Becker R, Triplett D, Cimini C, LaDuca F. Accurate and precise prothrombin time measurement in a multicenter anticoagulation trial employing patient self-testing. *Blood* 1995; 86(Suppl 1):864a.
  29. Triplett D, Andrew M, Cimini C, Becker D, **Ansell J**, Becker R, LaDuca F. Discrepancy of INR values in a multicenter anticoagulation maintenance trial attributable to ISI variability. *Blood* 1995; 86(Suppl 1):889a.
  30. Becker R, Becker D, Andrew M, **Ansell J**, Triplett D, Cimini C, LaDuca F. Anticoagulation Monitoring: Accurate results with patient self-testing in a multicenter clinical trial. *J Am Coll Cardiol* 1996; 27(suppl A):317A.
  31. Andrew M, **Ansell J**, Becker D, Becker R, Triplett D, Shepherd A. Multicenter trial of accurate home self-testing in oral anticoagulant patients with a novel whole blood system. *Blood* 1996; 88(suppl 1):179a.
  32. **Ansell J**. Increased testing frequency using ProTime Microcoagulation System in home testing suggests single point hospital testing may inaccurately assess anticoagulant status. *Thromb Hemostas* 1997; Suppl:84.
  33. Andrew M, **Ansell J**, Becker D, Becker R, Triplett D, Shepard A. A multi-center trial training oral anticoagulant patients to accurately self-test at home. *Thrombo Hemostas* 1997; Suppl:699.
  34. **Ansell JE**, Zweig S, Meyer B, Zehnder J, Lewis J. Performance of the Avocet<sub>PT</sub> prothrombin time system. *Blood* 1998;92(Suppl 1):112b.
  35. Sickels JM, **Ansell J**, Betz K, Lee J. A prospective, randomized, crossover study of the therapeutic effects of brand name Coumadin versus generic warfarin. *Pharmacother* 1998;18:1140.
  36. Sam, C, Speckman JL, Moskowitz MA, **Ansell JE**. The management of warfarin therapy by anticoagulation clinics. *J Gen Intern Med* 2000; (in press)

37. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor H376/95 with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: A phase II dose-finding study. *Blood* 2000; 96:491a.
38. Becker RC, Bovill EG, Dyke CK, Gardner L, Walker ME, Robertson TL, Kunitada S, **Ansell JE**, Hochman JS, Kleiman NS, Armstrong PW, Harrington RA. Response in plasma-based coagulation measurement to DX-9065a, a novel factor Xa inhibitor, infused in patients with stable coronary artery disease. *Thrombosis & Hemostasis* 2001
39. Finkelstein J, Nambu S, **Ansell J**. Computer-assisted education for patients on anticoagulation therapy. *Int J Behav Med* 2002;9:87-88.
40. Finkelstein J., Nambu S., **Ansell J**. Home Automated Telemanagement in patients on anticoagulation therapy. Proceedings of the 17<sup>th</sup> International Congress on Thrombosis. October 26-30, 2002, Bologna, Italy, 86.
41. Finkelstein J., Khare R., **Ansell J**. Home Automated Telemanagement in patients on anticoagulation therapy. *Pathophysiology of Haemostasis and Thrombosis* 2002; 32, in press.
42. Finkelstein J., Khare R., **Ansell J**. Acceptance of Home Automated Telemanagement in Patients on Anticoagulation Therapy. Accepted for presentation at American Thoracic Society International Conference, May 16-21, 2003, Seattle, Washington.
43. Schmitt L, Speckman J, **Ansell J**. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. *J Thromb Haemost* 2003; 1 Supplement 1 July:P1947.
44. Finkelstein J, Khare R, **Ansell J**. Home automated telemanagement affects quality of life in patients on anticoagulation therapy. *J Thromb Haemost* 2003; 1 Supplement 1 July: P1981
45. **Ansell J**. Current challenges in the management of thromboembolic disease. *J Thromb Haemost* 2003;1 supplement 1 July;S24.
46. Lassen MR, Davidson BL, Gallus A, Pineo G, **Ansell J**, Deitchman D. A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery. *Blood* 2003;102:15a..
47. Nutescu EA, Pickard AS, Blackburn JC, Wittkowsky AK, **Ansell J**, Schumock GT. Implications of oral direct thrombin inhibitors for anticoagulation clinics. ACCP 2004
48. **J Ansell** for the German ProTime Study Group. Oral anticoagulation therapy – The evolving role of patient self-testing and self-management and the need for optimized training programs. AACC Biannual Meeting, Warzburg, Ger, June 2004.
49. Ansell J, Salas M, Caro J, Proskorovsky I, Lordan N, Hauch O, Wygant G, Hollowell J, Bjorholt I. Quality of anticoagulation control in patients with chronic non-valvular atrial fibrillation managed in routine medical care in the United States. *International Society for Pharmacoeconomics and Outcomes Research*, 2005.
50. **Ansell J**, Caro J, Proskorovsky I, Lordan N, Salas M, Hauch O, Wygant G, Hollowell J, Bjorholt I. Quality of anticoagulation control in patients with atrial fibrillation managed in routine medical care in the US. *J Thrombo Thrombolys* 2005 (in press).

51. **J Ansell** for the German ProTime Study Group. Oral anticoagulation therapy – The evolving role of patient self-testing and self-management and the need for optimized training programs. Oral presentation at AHA, Nov 2005
52. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. A phase II randomized, double-blind, eight-arm, parallel-roup, dose-response study of apixaban, a new oral factor Xa inhibitor for the prevention of deep vein thrombosis in knee replacement surgery. *Blood* 2006;108:173a.